3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
101
Radiotherapy
53
Brachytherapy
41
Paclitaxel
37
Carboplatin
36
Surveys and Questionnaires
28
Blood Specimen Collection
20
pembrolizumab
19
Radiation
17
Magnetic Resonance Spectroscopy
17
Drug Therapy
17
Colposcopy
16
Methods
14
Bevacizumab
14
Early Intervention, Educational
12
toripalimab
11
Topotecan
11
Radiotherapy, Intensity-Modulated
11
Papanicolaou Test
11
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
11
Chemoradiotherapy
11
Biopsy
11
camrelizumab
10
Mass Screening
10
Gemcitabine
10
Patient Navigation
9
Papillomavirus Vaccines
9
Nivolumab
9
Fluorodeoxyglucose F18
9
Educational Status
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uterine Cervical Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled